Molecular imaging of prostate cancer: PET radiotracers

American Journal of Roentgenology

Volumn 199, Issue 2, 2012, Pages 278-291

  Jadvar, Hossein ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; CT; MRI; PET; Prostate

Indexed keywords

16BETA FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; 3' FLUOROTHYMIDINE F 18; 4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; 5 ETHYL 2' FLUOROURACIL ARABINOSIDE C 14; 5 ETHYL 2' FLUOROURACIL ARABINOSIDE F 18; 9 [4 FLUORO 3 (HYDROXYMETHYL)BUTYL]GUANINE F 18; ACETIC ACID; ACETIC ACID C 11; ANDROGEN RECEPTOR; ANTI 1 AMINO 3 FLUOROCYCLOBUTYL 1 CARBOXYLIC ACID F 18; CAPROMAB PENDETIDE IN 111; CHOLINE C 11; DESFERRIOXAMINE ZR 89; DOCETAXEL; FLUOROACETIC ACID F 18; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; METHIONINE C 11; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SODIUM FLUORIDE F 18; TESTOSTERONE; THYMIDINE C 11; TRACER; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; CANCER CELL; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION; GLEASON SCORE; GLUCOSE METABOLISM; HUMAN; LIPOGENESIS; LYMPH NODE METASTASIS; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RADIOISOTOPE DISTRIBUTION; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT RESPONSE; TUMOR RECURRENCE;

CARBON RADIOISOTOPES; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 84864762496     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.8816     Document Type: Review

References (218)

1. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castrate-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011; 29:3695-3704
2. Agarwal N, Sonpavde G, Sternberg CN. Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol 2012; 61:950-960
3. Mease RC. Radionuclide based imaging of prostate cancer. Curr Top Med Chem 2010; 10:1600-1616
4. Beheshti M, Langsteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009; 39:396-407
5. Hong H, Zhang Y, Sun J, Cai W. Positron emission tomography imaging of prostate cancer. Amino Acids 2010; 39:11-27
6. Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM. Molecular imaging of prostate cancer. Methods 2009; 48:193-199
7. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II. Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59:572-583
8. Bouchelouche K, Capala J, Oehr P. Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer. Curr Opin Oncol 2009; 21:469-474
9. Bouchelouche K, Tagawa ST, Goldsmith SJ, et al. PET/CT imaging and radioimmunotherapy of prostate cancer. Semin Nucl Med 2011; 41:29-44
10. Karam JA, Mason RP, Koeneman KS, Antich PP, Benaim EA, Hsieh JT. Molecular imaging in prostate cancer. J Cell Biochem 2003; 90:473-483 (Pubitemid 37243694)
11. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 2008; 49:2031-2041
12. Sanz G, Rioja J, Zudaire J, Berián JM, Richter JA. PET and prostate cancer. World J Urol 2004; 22:351-352 (Pubitemid 40227545)
13. Huang CW, Li Z, Cai H, Chen K, Shahinian T, Conti PS. Design, synthesis and validation of inetgrin a2b1-targeted probe for microPET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 2011; 38:1313-1322
14. 18F-FRGD2. J Nucl Med 2006; 47:113-121
15. Lepin EJ, Leyton JV, Zhou Y, et al. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging 2010; 37:1529-1538
16. Leyton JV, Olafsen T, Sherman MA, et al. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen expressing tumors. Protein Eng Des Sel 2009; 22:209-216
17. Leyton JV, Olafsen T, Lepin EJ, et al. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res 2008; 14:7488-7496
18. Olafsen T, Gu Z, Sherman MA, et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007; 30:396-405 (Pubitemid 46684429)
19. Vāvere AL, Lewis JS. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. Nucl Med Biol 2008; 35:273-279 (Pubitemid 351381965)
20. 18F-FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl Med Mol Imaging 2011; 38:1816-1823
21. 18F-EF5 and positron emission tomography. BJU Int 2007; 99:1154-1160 [Erratum in BJU Int 2007; 99:1161]
22. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr 2007; 39:251-257 (Pubitemid 47619378)
23. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008; 49(suppl 2):24S-42S (Pubitemid 351948035)
24. Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H. PET: a revolution in medical imaging. Radiol Clin North Am 2004; 42:983-1001 (Pubitemid 39361456)
25. Macheda ML, Rogers S, Bets JD. Molecular and cellular regulation of glucose transport (GLUT) proteins in cancer. J Cell Physiol 2005; 202:654-662 (Pubitemid 40175840)
26. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 2000; 57:170-178 (Pubitemid 30417071)
27. Effert P, Beniers AJ, Tamimi Y, Handt S, Jakse G. Expression of glucose transporter 1 (GLUT-1) in cell lines and clinical specimen from human prostate adenocarcinoma. Anticancer Res 2004; 24:3057-3063 (Pubitemid 39407186)
28. Stewart GD, Gray K, Pennington CJ, et al. Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter 1 expression correlate with Gleason score. Oncol Rep 2008; 20:1561-1567
29. Reinicke K, Sotomayor P, Cisterna P, Delgado C, Nualart F, Godoy A. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Biochem 2012; 113:553-562
30. Jadvar H, Xiankui L, Shahinian A, et al. Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging 2005; 4:91-97 (Pubitemid 43143795)
31. Kukuk D, Reischl G, Raguin O, et al. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models. J Nucl Med 2011; 52:1654-1663
32. 11C-aceatte in human prostate cancer cell lines? Eur J Nucl Med Mol Imaging 2011; 38:1842-1853
33. Jadvar H, Ye W, Groshen S, et al. [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med 2008; 22:787-793
34. Salminen E, Hogg A, Binns D, et al. Investigations with FDG PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 2002; 41:425-429 (Pubitemid 35222040)
35. Shiiba M, Ishihara K, Kimura G, et al. Evaluation of primary cancer using (11C)-methionine-PET/CT and (18)F-FDG-PET/CT. Ann Nucl Med 2011; 26:138-145
36. Minamimoto R, Uemura H, Sano F, et al. The potential of FDG PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med 2011; 25:21-27
37. Han EJ, Ho J, Choi WH, Yoo IR, Chung SK. Significance of incidental focal uptake in prostate on 18-fluoro-2-deoxyglucose positron emission tomography CT images. Br J Radiol 2010; 83:915-920
38. 18F-fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999; 29:623-629
39. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177:540-545 (Pubitemid 46054056)
40. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965-974
41. 18F- fluorodeoxyglucose positron emission tomography for detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005; 11:4761-4769
42. 18F-2-deoxyglucose positron emission tomography in patients with prostate specific antigen relapse after treatment for localized prostate cancer. Urol Int 2003; 70:311-315
43. 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med (in press)
44. Morris MJ, Akhurst T, Osman I, et al. Fluoridated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002; 59:913-918 (Pubitemid 34522186)
45. 11C-choline. J Nucl Med 2011; 52:81-89
46. Jadvar H, Pinski J, Quinn D, et al. PET/CT with FDG in metastatic prostate cancer: castrate-sensitive vs. castrate-resistant disease. J Nucl Med 2009; 50(suppl 2):460
47. Fox J, Morris MJ, Larson SM, Schöder H, Scher HI. Developing imaging strategies for castration resistant prostate cancer. Acta Oncol 2011; 50(suppl 1):39-48
48. Oyama N, Akino H, Suzuki Y, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 2001; 22:963-969 (Pubitemid 32783446)
49. Jadvar H, Desai B, Quinn D, et al. Treatment response assessment of metastatic prostate cancer with FDG PET/CT. J Nucl Med 2011; 52(suppl 1):1908
50. Jadvar H, Desai B, Ji L, et al. Comparison of imaging- and PSA-based treatment response criteria in metastatic prostate cancer: a preliminary analysis. 97th RSNA scientific assembly and annual meeting. Oak Brook, IL: Radiological Society of North America, 2011
51. Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the National Oncologic PET Registry. J Nucl Med 2008; 49:1928-1935
52. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002; 4:99-104 (Pubitemid 34272714)
53. 99mTc- MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res 2010; 16:6093-6099
54. 11C-acetate in prostate cancer: a biochemical, radiochemical, and clinical perspective. Eur J Nucl Med Mol Imaging 2008; 35:942-949
55. Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001; 28:117-122 (Pubitemid 32276075)
56. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006; 9:230-234 (Pubitemid 44317255)
57. 11Cacetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 2008; 49:327-334
58. Pflug BR, Pecher SM, Brink AW, et al. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. Prostate 2003; 57:245-254 (Pubitemid 37267807)
59. Seltzer MA, Jahan SA, Sparks R, et al. Radiation dose estimates in humans for (11)C-acetate wholebody PET. J Nucl Med 2004; 45:1233-1236 (Pubitemid 47611670)
60. 11C-acetate kinetics of prostate cancer. J Nucl Med 2008; 49:206-215
61. Kato T, Tsukamoto E, Kuge Y, et al. Accumulation of [(11)C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002; 29:1492-1495 (Pubitemid 35232052)
62. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43:181-186
63. Yu EY, Muzi M, Hackenvracht JA. C11-aceatte and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med 2011; 36:192-198
64. Kotzerke J, Volkmer BG, Neumaier B, et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2002; 29:1380-1384 (Pubitemid 44392221)
65. 11C-acetate for tumor detection and localization in patients with prostate specific antigen relapse after radical prostatectomy. Urology 2006; 67:996-1000
66. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44:549-555
67. 18F-fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging 2004; 31:797
68. 11C-acetate. J Nucl Med 2007; 48:420-428
69. Lindhe O, Sun A, Ulin J, Rahman O, Långström B, Sörensen J. [(18)F]Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology. Eur J Nucl Med Mol Imaging 2009; 36:1453-1459
70. 11C] choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42:25-30
71. Janardhan S, Srivani P, Sastry GN. Choline kinase: an important target for cancer. Curr Med Chem 2006; 13:1169-1186
72. 11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res 2011; 17:7673-7683
73. 18F]FDG in cultured prostate cancer cells. Nucl Med Biol 2006; 33:977-984
74. 11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005; 32:668-673
75. Reischl G, Bieg C, Schmiedl O, Solbach C, Machulla HJ. Highly efficient automated synthesis of [(11)C]choline for multi dose utilization. Appl Radiat Isot 2004; 60:835-838 (Pubitemid 38529847)
76. 11C-choline PET and PET-CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34:45-53
77. 11C)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005; 46:1642-1649
78. 11C-choline positron emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 2007; 99:1421-1426
79. 11C-choline positron emission tomography/computed tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006; 176:954-960
80. 11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res 2011; 17:3751-3759
81. 11C-choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumor stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008; 35:1065-1073
82. Testa C, Schiavina R, Lodi R, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET-CT. Radiology 2007; 244:797-806 (Pubitemid 47292091)
83. 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005; 32:742-748
84. 11C-choline PET-CT and whole body MRI for staging of prostate cancer. Nuklearmedizin 2007; 46:161-168
85. Beer AJ, Eiber M, Souvatzoglou M, et al. Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol 2011; 13:352-361
86. Park H, Piert MR, Khan A, et al. Registration methodology for histological sections and in vivo imaging of human prostate. Acad Radiol 2008; 15:1027-1039 (Pubitemid 351953912)
87. 11C-choline PET/CT for imaging prostate cancer: a pictorial guide. AJR 2011; 196:1390-1398
88. Picchio M, Crivellaro C, Giovacchini G, et al. PET-CT for treatment planning in prostate cancer. Q J Nucl Med Mol Imaging 2009; 53:245-268
89. Picchio M, Briganti A, Fanti S, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011; 59:51-60
90. Krause BJ, Souvatzpglou M, Tuncel M, et al. The detection rate of [(11)C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:18-23 (Pubitemid 350234152)
91. Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000; 27:1415-1419
92. 11C]choline positron emission tomography in patients with increasing prostatespecific antigen levels after primary treatment for prostate cancer. BJU Int 2007; 100:786-793
93. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003; 44:32-38
94. 11C)] choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008; 35:9-17
95. 11C] choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007; 52:423-429
96. 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009; 50:1394-1400
97. 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol 2010; 12:210-217
98. 11C]choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012; 39:13-26
99. 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 2011; 38:1985-1989
100. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61:110-117
101. 18F)F-fluorocholine for prostate cancer imaging: a systematic review of literature. Prostate Cancer Prostatic Dis 2012; 15:45-55
102. Price DT, Coleman RE, Liao RP, et al. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168:273-280 (Pubitemid 34640843)
103. Jadvar H, Gurbuz A, Li X, et al. Choline autoradiography of human prostate cancer xenograft: effect of castration. Mol Imaging 2008; 7:147-152
104. 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localization of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:976-983
105. Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 2005; 173:252-255 (Pubitemid 39627729)
106. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254:925-933
107. 18F)-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med (Torino) 2008; 113:895-904
108. Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18 fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/mL? Mol Imaging Biol 2006; 8:43-48 (Pubitemid 44193401)
109. 18F-fluorolcholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012; 39:271-282
110. Schillaci O, Calabria F, Tavolozza M, et al. Influence of PSA, PSA velocity, and PSA doubling time on contrast-enhanced (18)F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging 2012; 39:589-596
111. 18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging 2011; 55:448-457
112. 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008; 35:1766-1774
113. Beheshti M, Vali R, Waldenberger P, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 2009; 11:446-454
114. 18F- fluorodeoxyglucose PET. Nat Rev Urol 2009; 6:317-323
115. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005; 43:153-167 (Pubitemid 40326566)
116. 18F]-FDG? Bull Cancer 2005; 92:789-798
117. Nimmagadda S, Shields AF. The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer Metastasis Rev 2008; 27:575-587
118. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med 2008; 49(suppl 2):64S-80S (Pubitemid 351948037)
119. Shields AF, Mankoff DA, Graham MM, et al. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. J Nucl Med 1996; 37:290-296 (Pubitemid 26150906)
120. 11C] Thymidine and FDG to measure therapy response. J Nucl Med 1998; 39:1757-1762
121. Mankoff DA, Shield AF, Graham MM, Link JM, Eary JF, Krohn KA. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med 1998; 39:1043-1055 (Pubitemid 28270124)
122. 11C]thymidine PET imaging studies: validation studies. J Nucl Med 1999; 40:614-624
123. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4:1334-1336 (Pubitemid 28512118)
124. 18F)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000; 27:143-156
125. Shields AF, Grierson JR, Muzik O, et al. Kinetics of 3′-deoxy- 3′-[F-18]fluorothymidine uptake and retention in dogs. Mol Imaging Biol 2002; 4:83-89
126. Oyama N, Ponde D, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2004; 45:519-525 (Pubitemid 47618630)
127. 18F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumor models. Eur J Nucl Med Mol Imaging 2011; 38:81-89
128. Tehrani OS, Douglas KA, Lawhorn-Crews JM, Shields AF. Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. Eur J Nucl Med Mol Imaging 2008; 35:1480-1488
129. Fanucchi MP, Leyland-Jones R, Young CW, et al. Phase I trial of 1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU). Cancer Treat Rep 1985; 69:55-59
130. 11C]- FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol 1995; 22:783-789
131. Bading JR, Shahinian AH, Bathija P, Conti PS. Pharmacokinetics of the thymidine analog 2′-fluoro-5-[(14)C]-methyl-1-beat-D- arabinofuranosyluracil ([(14)C]FMAU in rat prostate tumor cell. Nucl Med Biol 2000; 27:361-368 (Pubitemid 30628696)
132. Wang H, Oliver P, Nan L, et al. Radiolabeled 2′-fluorodeoxyuracil- beat-D-arabinofuranoside (FAU) and 2′-fluoro-5-methyldeoxyuracil-beta-D- arabinofuranoside (FMAU) as tumor imaging agents in mice. Cancer Chemother Pharmacol 2002; 49:419-424
133. 18F-fluoro-beta-D-arabinofuranosyl) thymine and PET. J Nucl Med 2007; 48:1436-1441
134. 18F] labeled FAU, FMAU, FBAU, FIAU. Nucl Med Biol 2003; 30:215-224
135. de Vries EF, van Waarde A, Harmsen MC, et al. [(11)C]FMAU and [(18)F]FHPG as PET tracers for herpes simplex virus thymidine kinase activity and human cytomegalovirus infections. Nucl Med Biol 2000; 27:113-119 (Pubitemid 30205631)
136. Alauddin MM, Shahinian A, Gordon EM, Conti PS. Evaluation of 2′-deoxy-2′-fluoro-5-methyl-1-beta-D-arabinofurasyluracil as a potential gene imaging agent for HSV-tk expression in vivo. Mol Imaging 2002; 1:74-81
137. 18F-fluoro-5- fluoro-1-beta-D-arabinofuranosyluracil as a potential PET imaging agent for suicide gene expression. J Nucl Med 2004; 45:2063-2069
138. 3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type I thymidine kinase in cell culture. Mol Imaging Biol 2005; 7:296-303
139. 18F]-FMAU) using a one reactor radiosynthesis module. Nucl Med Biol 2011; 38:201-206
140. ?-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats. Nucl Med Biol 2004; 31:407-418
141. Conti PS, Bading JR, Mouton PP, et al. In vivo measurement of cell proliferation in canine brain tumor using C-11-labeled FMAU and PET. Nucl Med Biol 2008; 35:131-141 (Pubitemid 350298247)
142. Nishii R, Volgia AY, Mawlawi O, et al. Evaluation of 2′-deoxy- 2′-[(18)F]fluoro-5-methyl-1-beta-L:- arabinofuranosyluracil ([(18)F]-L:-FMAU) as a PET imaging agent for cellular proliferation: comparison with [(18)F]-D:-FMAU and [(18)F]FLT. Eur J Nucl Med Mol Imaging 2008; 35:990-998
143. 18F-FMAU and PET. J Nucl Med 2005; 46:292-296
144. Shields AF. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol 2006; 8:141-150 (Pubitemid 44193390)
145. Doeg KA, Polomski LL, Doeg LH. Androgen control of mitochondrial and nuclear DNA synthesis in male sex accessory tissue of castrate rats. Endocrinology 1972; 90:1633-1638
146. 18F-FMAU) in prostate cancer: initial preclinical observations. Mol Imaging (in press)
147. 18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging 2005; 32:15-22
148. Alauddin MM, Shahinian A, Gordon EM, Conti PS. Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. Mol Imaging 2004; 3:76-84
149. 18F]FIAU) using a multistep one-pot strategy. Nucl Med Biol 2011; 38:659-666
150. Trapman J, Brinkmann AO. The androgen receptor in prostate cancer. Pathol Res Pract 1996; 192:752-760 (Pubitemid 26302249)
151. Culig Z, Hobisch A, Hittmair A, et al. Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Drugs Aging 1997; 10:50-58 (Pubitemid 27057937)
152. Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999; 26:407-421 (Pubitemid 29411449)
153. Scher HI, Beer TM, Higano CS, et al. Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437-1446
154. Morris M, Huang D, Kelly W, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 2009; 56:237-244
155. Liu A, Dence CS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six
156. 18F]fluoro- 4-nitronaphthyl)-cis-5- norobornene-endo-2,3-dicarboxylic imide. Nucl Med Biol 2006; 33:615-624
157. Parent EE, Carlson KE, Katzenellenbogen JA. Synthesis of 7alpha-(fluormethyl)dihydrotetosterone and 7alpha-(fluoromethyl) nortestosteerone, structurally paired androgens designed to probe the role of sex hormone binding in imaging androgen receptors in prostate tumors by emission tomography. J Org Chem 2007; 72:5546-5554 (Pubitemid 47104655)
158. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004; 45:366-373
159. Dehdashti F, Picus J, Michalski J, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005; 32:344-350 (Pubitemid 40562127)
160. 18F-fluoro-5alpha-dihydrotestosterine (FDHT) in prostate tumors as measured by PET. J Nucl Med 2010; 51:183-192
161. Fox J, Blanc E, Schoder H, et al. Diversity of biology in castrate resistant prostate cancer. J Nucl Med 2009; 50(suppl 2):523
162. 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 2004; 45:1966-1971
163. 64Cu-labaled bombesin analogs in a mouse model of human prostate cancer. Nucl Med Biol 2006; 33:371-380
164. 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004; 45:1390-1397
165. Yang M, Gao H, Zhou Y, et al. F-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging. Theranostics 2011; 1:220-229
166. 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med 2011; 52:470-477
167. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med 2011; 52:270-278
168. 64Cu-NO2A- (X)- BBN(7-14)NH2], in a prostate tumor xenografted mouse model. Nucl Med Biol 2010; 37:751-761
169. Ananias HJ, de Jong IJ, Diercks RA, van de Wiele C, Helfrich W, Elsinga PH. Nuclear imaging of prostate cancer with gastrin-releasing receptor targeted radiopharmaceuticals. Curr Pharm Des 2008; 14:3033-3047
170. 64Cu-bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 2007; 48:1327-1337
171. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 2006; 47:492-501
172. Rogers BE, Bigott HM, McCarthy DW, et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analog. Bioconjug Chem 2003; 14:756-763 (Pubitemid 36875435)
173. Craft JM, De Silva RA, Lears KA, et al. In vitro and in vivo evaluation of a (64)Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrinreleasing peptide receptor expressing prostate cancer. Nucl Med Biol 2012 [Epub ahead of print]
174. Schroeder RP, van Weerden WM, Krenning EP, et al. Gastrin-releasing receptor-based targeting using bombesin analogs is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging 2011; 38:1257-1266
175. 18F)F]fluoro-2- deoxy-D-glucose (FDG) in androgen independent prostate cancer. Clin Positron Imaging 1999; 2:173-181
176. 11C-methionine PET scans in pati8ents with newly progressive metastatic prostate cancer. J Nucl Med 2002; 43:46-55
177. 11C-methionine positron emission tomography. J Urol 2005; 173:66-69
178. 18F-fluorocyclobutyl- 1-carboxylic acid for the detection of prostate cancer. J Nucl Med 2007; 48:46-55
179. 14C) cyclobutanecarboxylic acid in prostate cancer. Nucl Med Biol 2012; 39:109-119
180. 18F-fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med 2011; 52:822-829
181. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007; 48:56-63
182. 18F-fluorocyclobutane-1- carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology 2011; 259:852-861
183. 18F-fluorocyclobutane-1-carboxylic acid (anti-[F-18]FACBC) to guide prostate cancer radiotherapy target design. Clin Nucl Med 2009; 34:279-284
184. Tombal B, Lecouvet F. Modern detection of prostate cancer's bone metastasis: is the bone scan era over? Adv Urol 2012; 2012:893193
185. Shirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999; 40:1623-1629 (Pubitemid 29471151)
186. 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008; 49:68-78
187. 18F-NaF deposition. J Nucl Med 2010; 51:1826-1829
188. 18F-fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med 2007; 37:462-469
189. Li Y, Tafti BA, Shaba W, Berenji GR. Superscan pattern of F-18 sodium fluoride PET/CT study in a case of prostate cancer. Clin Nucl Med 2011; 36:1046-1048
190. 18F-fluoride PET/CT bone scans 1.0. J Nucl Med 2010; 51:1813-1820
191. 18F-fluoride PET/CT. J Nucl Med 2008; 49:414-421
192. 18F-fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT. Ann Nucl Med 2010; 24:241-247
193. 18F-fluoride PET/CT. J Nucl Med 2006; 47:287-297
194. 18F-fluoriode: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res 2011; 1:4
195. 18F-fluoride ion PET bone scanning. AJR 2006; 186:1783-1786
196. Bouchelouche K, Choyke PL, Capala J. Prostate-specific membrane antigen: a target for imaging and therapy with radionuclides. Discov Med 2010; 9:55-61
197. Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with positron emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA 2011; 108:9578-9582
198. Haseman MK, Rosenthal SA, Polascik TJ. Capromab pendetide imaging of prostate cancer. Cancer Biother Radiopharm 2000; 15:131-140 (Pubitemid 30305964)
199. Ruggiero A, Holland JP, Hudolin T, et al. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immunoPET. J Nucl Med 2011; 52:1608-1615
200. 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate 2010; 70:1413-1421
201. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 2010; 53:5333-5341
202. Elsässer-Beile U, Reischl G, Wiehr S, et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009; 50:606-611
203. 18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 2011; 17:7645-7653
204. Holland JP, Divilov V, Bander NH, et al. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010; 51:1293-1300
205. 18F]-DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res 2008; 14:3036-3043
206. 18F- labeld phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med 2009; 50:2042-2048
207. Adams JY, Johnson M, Sato M, et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 2002; 8:891-897
208. Sato M, Johnson M, Zhang L, et al. Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy. Mol Ther 2003; 8:726-737 (Pubitemid 37527447)
209. Zhang L, Adams JY, Billick E, et al. Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther 2002; 5:223-232 (Pubitemid 34211217)
210. Iyer M, Wu L, Carey M, Wang Y, Smallwood A, Gambhir SS. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci USA 2001; 98:14595-14600 (Pubitemid 33121437)
211. Sato M, Figueiredo ML, Burton JB, et al. Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging. Gene Ther 2008; 15:583-593
212. Pouliot F, Karanikolas BD, Johnson M, et al. In vivo imaging of intraprostatic-specific gene transcription by PET. J Nucl Med 2011; 52:784-791
213. Jiang ZK, Sato M, Wei LH, Kao C, Wu L. Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer. Cancer Res 2011; 71:6250-6260
214. Sato M, Johnson M, Zhang L, Gambhir SS, Carey M, Wu L. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin Cancer Res 2005; 11:3743-3749 (Pubitemid 40685591)
215. Burton JB, Johnson M, Sato M, et al. Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med 2008; 14:882-888
216. 18F-FHBG PET imaging in prostate cancer. J Nucl Med 2009; 50:757-764
217. Johnson M, Sato M, Burton J, Gambhir SS, Carey M, Wu L. MicroPET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach. Mol Imaging 2005; 4:463-472 (Pubitemid 43143786)
218. Giovacchini G, Picchio M, Briganti A, et al. [11C]Choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol 2010; 184:938-943